Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.

Overall, baricitinib was well tolerated and resulted in clinical improvement in AD patients in a real-world clinical setting. Additionally, baricitinib may be beneficial in treating lesions refractory to dupilumab therapy.